Private-Equity Investors Poised To Acquire Nestlé Skin Health, Promising US Expansion
Executive Summary
After working hard to turnaround its troubled Skin Health dermatology operation, Nestlé looks set to offload the business to a consortium of private-equity buyers. The consortium - led by EQT - have identified expansion in the US consumer health market as an immediate priority.
You may also be interested in...
Nestle Pairs Nutrition Science Business With Pharma Firm Making Peanut Allergy Treatment
Nestle agrees to acquire Aimmune Therapeutics, maker of a drug indicated to reduce the severity of children’s allergic reactions to peanuts. It anticipates options to innovate in its consumer health children’s allergy business.
EU Business Round-Up: Galderma Divests To Dallman’s, Oysershell names CEO, Ceres Acquires
Latest business news in the EU: Galderma offloads German Bübchen brand to Dallman's; Belgium's Oystershell names experienced CEO; Ceres Pharma snaps up Romania's Viva.
Nestlé Skin Health Has Suitors ‘Lining Up Around The Block’ After ‘Stunning’ Sales Turnaround
Nestlé's once troubled Skin Health business is now a "leader in its space" after an astonishing turnaround, according to the Swiss firm's CEO. What's more, potential buyers for the unit are queuing out the door, waiting for Nestlé to kick off a much anticipated sale process.